In a child with IgA-mediated bullous pemphigoid not fully controlled by topical steroids, how should dapsone be used as a steroid‑sparing agent, including dosing, monitoring, contraindications, and alternative therapies?

Dapsone for IgA Bullous Pemphigoid in Children

Primary Recommendation

In children with IgA-mediated bullous pemphigoid inadequately controlled by topical steroids, erythromycin (1000-3000 mg daily in adults, weight-adjusted for children) should be tried first before dapsone, as it has demonstrated efficacy specifically in pediatric populations with an acceptable safety profile. 1

Treatment Algorithm

First-Line Approach for Pediatric Cases

• Erythromycin is specifically recommended for children with bullous pemphigoid, showing beneficial effects within 1-3 weeks, often combined with topical corticosteroids 1
• This recommendation stems from case series involving children and adults where erythromycin demonstrated effectiveness with fewer safety concerns than dapsone in the pediatric population 1

When to Consider Dapsone

Dapsone should be reserved as a second-line steroid-sparing agent only after erythromycin or other first-line treatments prove ineffective or are contraindicated 1

Dosing Strategy

• Start at 1-2 mg/kg/day for children (adult equivalent: 50-200 mg daily) 2, 3
• In one pediatric case with SLE-associated bullous pemphigoid, dapsone 1 mg/kg/day achieved dramatic resolution of skin lesions 4
• Response is slower than systemic corticosteroids, typically requiring 2-3 weeks 1
• The combination of dapsone 0.5-1.0 mg/kg/day with methylprednisolone 0.5 mg/kg/day showed 32% complete remission at 2 weeks in adults 1

Critical Pre-Treatment Requirements

Mandatory Screening

• Screen for G6PD deficiency before initiating dapsone, particularly in males of African, Mediterranean, or Asian ancestry, as G6PD deficiency dramatically increases severe hemolysis risk 2
• This is non-negotiable and must be excluded in predisposed populations 1

Monitoring Protocol

Hematologic Surveillance

• Monitor complete blood counts regularly as dose-related hemolysis and methemoglobinemia are the most common adverse effects, even in G6PD-normal patients 2
• Hemolysis is expected in most patients and is usually reversible 5
• In one series, 5% of patients developed serious hematologic complications (2 with hemoglobin <7 g/dL, 1 with agranulocytosis) 3

Warning Signs Requiring Immediate Discontinuation

• Dapsone hypersensitivity syndrome: fever, exfoliative dermatitis, hepatic dysfunction, methemoglobinemia occurring 1-4 weeks into therapy 2
• Severe anemia (hemoglobin <7 g/dL) or agranulocytosis 3
• Peripheral neuropathy (rare but reported, predominantly affecting motor function) 2

Evidence Quality and Limitations

The evidence for dapsone in bullous pemphigoid is weak (Level 3-4 evidence, Strength of Recommendation D) 1. There are no randomized controlled trials for dapsone as monotherapy or adjunct specifically in bullous pemphigoid 1. The available data comes from:

• Four retrospective series totaling 110 patients showing 45% response rate in three series, but only 15% in the fourth 1
• One RCT comparing dapsone to azathioprine showed dapsone had moderately higher steroid-sparing potential (median cumulative corticosteroid dose 1.92g vs 2.65g), though not statistically significant 6

Alternative Steroid-Sparing Agents

If Dapsone Fails or Is Contraindicated

• Azathioprine 1.5-2.5 mg/kg/day is the most commonly used steroid-sparing agent after systemic corticosteroids, though evidence for its efficacy is conflicting 1
• Measure thiopurine methyltransferase (TPMT) activity before starting to optimize dosing and minimize myelosuppression risk 1
• Mycophenolate mofetil 0.5-1g twice daily showed similar efficacy to azathioprine in one RCT, though slower to achieve remission (42 vs 28.6 days) 1
• Methotrexate (maximum 15 mg weekly) can be effective as monotherapy or combined with topical steroids, though evidence is limited to small case series 1

Critical Caveats

• The side-effect profile of dapsone is potentially hazardous in the elderly and requires careful consideration in vulnerable populations 1
• Dapsone should only be considered when other treatments are ineffective or contraindicated 1
• The overall response rate to dapsone in bullous pemphigoid (81%) is lower than in mucous membrane pemphigoid (84%) 5
• Note: The question specifically asks about IgA bullous pemphigoid, but the provided evidence primarily addresses standard (IgG-mediated) bullous pemphigoid. IgA-mediated disease may respond differently, though specific pediatric data is extremely limited 4